Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Alcohol Use Disorder (AUD), HIV
Interventions: semaglutide; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Ulcerative Colitis
Interventions: RO7837195, RO7837195 Matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 6 more

Conditions: Ovarian Cancer
Interventions: ABBV-901, Bevacizumab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Denver, Colorado + 5 more

Conditions: Physical Activity, Weight
Interventions: TV commercial stepping, 30-min walk; Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 25 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Breast Cancer Metastatic
Interventions: Avasopasem; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 31
States / cities: Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more

Conditions: Locally Advanced or Metastatic Breast Cancer
Interventions: Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Adolescent Obesity
Interventions: Lifestyle Modification Therapy (LSMT), Phentermine Pill, Topiramate Pill, Placebo; Behavioral · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Depression
Interventions: Outreach messaging; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Honolulu, Hawaii • Detroit, Michigan

Conditions: Diabetes
Interventions: Soccer-based adaptation to the DPP; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 35 Years to 55 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pancreas Cancer, Gastrointestinal Adenocarcinoma
Interventions: ultrasound; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Remission
Interventions: Tibetree Pain Relieving Plaster, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pneumococcal Vaccines
Interventions: 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 45
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 10
States / cities: Birmingham, Alabama • Fresno, California • Jacksonville, Florida + 6 more

Conditions: Weight Loss, Obesity and Overweight
Interventions: BrainWeighve App; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 21 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Colorectal Cancer
Interventions: All eligible subjects will provide blood for SEPT9 biomarker testing; Other
Lead sponsor: Epigenomics, Inc; Industry
Eligibility: 50 Years and older
Enrollment: 7,929 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Boca Raton, Florida • Miami, Florida • Atlanta, Georgia + 15 more

Conditions: Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: SUN-627, Placebo; Drug · Other
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Hemophilia A
Interventions: NXT007, Human Coagulation Factor VIII; Combination Product · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Aurora, Colorado • Iowa City, Iowa

Conditions: Endometrial Cancer
Interventions: retifanlimab, epacadostat, pemigatinib, INCAGN02385, INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 29
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Type2 Diabetes
Interventions: Positive Psychology + Motivational Interviewing, MI-based Health Education Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Interventions: BIIB059 (litifilimab), Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 53
States / cities: Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec, placebo; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 7 Years · Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more

Conditions: Small Cell Lung Cancer
Interventions: Tarlatamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Orlando, Florida • Grand Rapids, Michigan • Omaha, Nebraska

Search by objective public record fields.

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

Physical Activity and Leisure-time Study (PALS)

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

SMART Use of Medication for the Treatment of Adolescent Severe Obesity

Outreach to Reduce Depression Disparities

Soccer-based Adaptation of the Diabetes Prevention Program

An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BrainWeighve App Feasibility Study

PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)